# A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

> **NCT02334436** · PHASE3 · COMPLETED · sponsor: **Evolus, Inc.** · enrollment: 324 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** Botulinum toxin, Type A
- **OTHER:** 0.9% sterile, unpreserved saline

## Key facts

- **NCT ID:** NCT02334436
- **Lead sponsor:** Evolus, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-09
- **Final completion:** 2015-12
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2019-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334436, "A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02334436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*